BioSpace News Archive

Brooklyn ImmunoTherapeutics, Inc today announces that Brooklyn has been named to be part of the Nasdaq Biotechnology Index (Nasdaq:NBI), effective December 20, 2021.

Positive data from two Phase 3 studies evaluating the efficacy and safety of fitusiran, an investigational small interference RNA (siRNA) therapy for the prophylactic treatment of adults and adolescents with hemophilia A or B, with or without inhibitors, are presented at the 63rd American Society of Hematology (ASH) Annual Meeting.

Clearday, Inc. (OTCQB: CLRD) announced today that John Bergeron joined the company as chief financial officer effective December 8, 2021.

Fitusiran, an experimental hemophilia therapy administered through a monthly subcutaneous injection, met its primary endpoint in a phase III trial being presented at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition.

Secura Bio, Inc. (Secura Bio) - (www.securabio.com), today announced that new data for the treatment of relapsed or refractory(r/r) PTCL patients with COPIKTRA were presented at the 63rd annual meeting of the American Society of Hematology (ASH) in Atlanta, Georgia.

Elemental Machines, a manufacturer of universal laboratory asset management technology for research, clinical, and testing labs around the world, today announced its successful acquisition of the Tetra Lab Monitoring business from Boston-based TetraScience.

DURECT Corporation announced the expansion of its board of directors with the appointment of Peter García, a biopharmaceutical industry veteran with over 25 years of financial leadership experience.

The Lupus Research Alliance proudly announced 11 research grant recipients in the U.S. and around the world of the 2021 Lupus Innovation Award which will fund wide ranging areas from probing the development and progression of lupus to pointing to potential personalized therapies.

Neutron Therapeutics, a targeted radiation therapy company developing a comprehensive solution for Boron Neutron Capture Therapy (BNCT), announced today that it has appointed Elizabeth Reczek, Ph.D., as its Chief Executive Officer and member of its Board of Directors.

Growing geriatric population and increasing molecular, pathological, and immunological tests are expected to bolster market growth.